Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
The Journal of Pharmacology and Experimental Therapeutics
|
November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid Malignancies
Niu Shin, Yun-Long Li, Song Mei, et al.
Journal of Medicinal Chemistry
|
May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
Jincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
ACS Medicinal Chemistry Letters
|
November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
Eddy W Yue, Yun-Long Li, Brent Douty, et al.
Cancer Biology & Therapy
|
April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells
Phillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Journal of Medicinal Chemistry
|
January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer
Wenqing Yao, Jincong Zhuo, David M Burns, et al.
Cancer Discovery
|
March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Journal of Medicinal Chemistry
|
January 8, 2025
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Qinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Matthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
China CDC Weekly
|
October 1, 2021
COVID-19 Outbreak Caused by Contaminated Packaging of Imported Cold-Chain Products - Liaoning Province, China, July 2020
Huilai Ma, Jianqun Zhang, Ji Wang, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
The Journal of Pharmacology and Experimental Therapeutics
|
November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid Malignancies
Niu Shin, Yun-Long Li, Song Mei, et al.
Journal of Medicinal Chemistry
|
May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
Jincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
ACS Medicinal Chemistry Letters
|
November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
Eddy W Yue, Yun-Long Li, Brent Douty, et al.
Cancer Biology & Therapy
|
April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells
Phillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Journal of Medicinal Chemistry
|
January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer
Wenqing Yao, Jincong Zhuo, David M Burns, et al.
Cancer Discovery
|
March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Journal of Medicinal Chemistry
|
January 8, 2025
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Qinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Matthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
China CDC Weekly
|
October 1, 2021
COVID-19 Outbreak Caused by Contaminated Packaging of Imported Cold-Chain Products - Liaoning Province, China, July 2020
Huilai Ma, Jianqun Zhang, Ji Wang, et al.
Page
of 11